ICON Public Company (ICLR) Q4 2024 earnings summary

Executive summary

• Full-year 2024 revenue grew 2% to $8.28 billion, with Q4 revenue at $2.04 billion; adjusted EPS rose 9.5% to $14.00, and Q4 adjusted EPS was $3.43.

• Backlog increased 8.3% year-over-year to $24.7 billion at year-end.

• Net business wins for 2024 totaled $9,974 million with a book-to-bill of 1.20; Q4 net business wins were $2,413 million with a book-to-bill of 1.18.

• The business environment remains mixed and volatile, with positive leading indicators and improved opportunity flow, especially in biotech.

• Digital innovation and automation strategies are delivering operational efficiencies, with over $100 million in annual savings expected.

Financial highlights

• Q4 adjusted EBITDA was $423 million (20.7% margin), down 5.7% year-over-year; full-year adjusted EBITDA was $1.74 billion (21% margin), up 2.5%.

• Free cash flow for 2024 was $1.1 billion, up 10% from 2023.

• Net income for 2024 was $791.5 million, up from $612.3 million in 2023.

• Q4 adjusted net income was $282 million (13.8% margin); Q4 GAAP net income was $260 million ($3.16 per share).

• Net debt at year-end was $2.9 billion, with a leverage ratio of 1.7x net debt to adjusted EBITDA.

Outlook and guidance

• 2025 guidance reaffirmed: revenue $8,050–$8,650 million and adjusted EPS $13.00–$15.00.

• Book-to-bill ratio target of at least 1.2x on a trailing 12-month basis maintained.

• Pass-through revenue mix expected to increase in H1 2025, pressuring EBITDA margin by about 1% for the year.

• Cancellations expected to remain elevated in 2025, factored into guidance.

• Capital expenditure for 2025 is expected to be approximately $200 million.